NOVARTIS MERGER DOES NOT AFFECT SCOPE OF SANDOZ/GTI GENE THERAPY PATENT -- FTC's AZCUENAGA; AGENCY CITES NEED FOR "RIVAL CENTERS" OF INTELLECTUAL PROPERTY
The merger of Ciba and Sandoz "does not add to the scope of the patent monopoly" created by Sandoz' patent on ex vivo gene therapy, FTC Commissioner Mary Azcuenaga asserts in a separate statement on the Federal Trade Commission's proposed consent order that would require Novartis to grant licenses to the patent.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth